Search results - 4 results
Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework.
ImmunoAssay (GP5 +/6+ EIA) using the VALGENT (VAL idation of HPV GEN otyping Tests) framework. METHODS: Clinical performance was assessed using 998 unselected, cervical screening samples enriched with 297 ...
Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
immunoassay (standard comparator assay). Non-inferior accuracy detecting cervical intraepithelial neoplasia of grade 2 or worse (CIN2 +) of the index versus comparator was verified. Intra- and interlaboratory ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
relative sensitivity and specificity compared to Hybrid Capture-2 or GP5 +/6+ PCR –enzyme immunoassay. These latter two hrHPV DNA assays were validated in large randomized trials and cohorts with a follow-up ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
+/6+ PCR, with a genotyping readout as an alternative for the more established enzyme immunoassay (EIA) detection of 14 targeted high-risk human papillomavirus (HPV) types. LMNX is additionally provided ...